期刊文献+

三种积分系统评估骨髓增生异常综合征预后的价值

THE VALUE OF IPSS-R,WPSS AND WDAPSS SCORING SYSTEMS FOR PROGNOSTIC ASSESSMENT OF MYELODYSPLASTIC SYNDROME
下载PDF
导出
摘要 目的比较IPSS-R、WPSS和WDAPSS三种积分系统评估骨髓增生异常综合征(MDS)预后的价值。方法回顾性分析潍坊市人民医院收治的80例MDS病人的临床及实验室检查资料,应用Kaplarl-Meier方法绘制生存曲线,各积分系统按照危险度对MDS病人进行分组,比较各积分系统不同组的生存期。结果各积分系统不同组的生存期差异均有统计学意义(χ2=30.532~56.710,P〈0.01)。IPSS-R与WPSS相关性最强(r=0.870,P〈0.01),WDAPSS与WPSS相关性次之(r=0.807,P〈0.01),IPSS-R与WDAPSS相关性较差(r=0.715,P〈0.01)。结论三种积分系统均能较好预测MDS病人的预后,综合运用不同的积分系统将病人分组,有助于早期评估MDS病人预后。 Objective To compare the value of IPSS-R, WPSS and WDAPSS scoring systems in predicting the prognosis of myelodysplastic syndrome (MDS). Methods The clinical and laboratory data of 80 patients with MDS treated in Weifang People's Hospital were retrospectively reviewed. Using Kaplan Meier method, a survival curve was made. The three score systems were used to divide the patients into several groups according to the risk factor. The life span in patients between each scoring system was compared. Results The difference of life span between different groups was statistically significant (χ2=30.532-- 56.710,P〈0.01). IPSS-R was most strongly correlated with WPSS (r=0.870,P〈0.01), followed by WDAPSS and WPSS (r= 0.807,P〈0.01), and IPSS-R and WDAPS (r=0.715,P〈0.01). Conclusion All the three scoring systems can better predict the prognosis of patients with myelodysplastic syndrome. Integrated use of different scoring system to divide patients into several groups is conducive to early prediction of prognosis of patients with this condition.
出处 《齐鲁医学杂志》 2015年第3期270-272,共3页 Medical Journal of Qilu
关键词 骨髓增生异常综合征 IPSS-R积分系统 WPSS积分系统 WDAPSS积分系统 预后 myelodysplastic syndrome IPSS-R scoring system WPSS scoring system WDAPSS scoring system prognosis
  • 相关文献

参考文献11

  • 1GU1LLERMO G M. Myelodysplastic Syndromes: 2014 update on diagnosis, risk-stratification and management[J]. Am J Hematology, 2014,89 : 97-105. 被引量:1
  • 2MALCOVATI L, DELLA PORTA M G, STRUPP C A, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) [J]. Haematologica-- The Hematology Journal, 2011,96 ( 10 ) : 1433-1440. 被引量:1
  • 3MALCOVATI L, HELLSTROM-LINDBERG E, BOWEN D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults recommendations from the European Leukemia Net[J]. Blood, 2013,122(17) :2943-2964. 被引量:1
  • 4韩乐乐,吴春梅.骨髓增生异常综合征142例染色体核型分析[J].青岛大学医学院学报,2014,50(3):227-229. 被引量:2
  • 5YANG Y T, HOU H A, LIU C Y, et al. IPSS-R in 555 Tai- wanese patients with primary MDS: integration o[ monosomal karyotype can better risk-stratify the patients[J]. American Journal of Hematology, 2014,89(9)= E142-E149. 被引量:1
  • 6REIS-ALVES S C, TRAINA F, HARADA G A, et al. Im- munophenotyping in rnyelodysplastic syndromes can add prog- nostic information to Well-Established and new clinical scores [J]. PLOS One, 2013,8(12), e81048. 被引量:1
  • 7MISHRA A, CORRALES-YEPEZ M, ALI N A, et al. Vali- dation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes[J]. Ameri can Journal of Hematology, 2013,88(7).-566-570. 被引量:1
  • 8隗佳,陈燕.骨髓增生异常综合征预后因素研究新进展[J].中国实验血液学杂志,2008,16(6):1465-1472. 被引量:2
  • 9ZEIDAN A M, KOMROKJI R T. There's risk, and then there's risk: the latest clinical prognostic risk stratification models in myelodysplastic syndromes[J]. Current Hematolo- gic Malignancy Reports, 2013,8(4) :351-360. 被引量:1
  • 10LORAND-METZE J, CALIFANI S M, RIBEIRO E, et al. The prognostic value of maturation-associated phenotypic ab- nomaiities in myelodysplastic syndromes[J]. Leuk Res, 2008, 32:211-213. 被引量:1

二级参考文献66

  • 1王小钦,林果为.282例原发性骨髓增生异常综合征诊断和分型的前瞻性临床研究[J].中华血液学杂志,2006,27(8):546-549. 被引量:34
  • 2Babicka L, Ransdorfova S, Brezinova J, et al. Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. Leuk Res, 2007 ;31:39 -47 被引量:1
  • 3Mohamedali A, Gaken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood, 2007; 110:3365 - 3373 被引量:1
  • 4Malcovati L, Della Porta MG, Luughi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia, 2005 ; 19:776 - 783 被引量:1
  • 5Arroyo JL, Femandez ME, Hem6ndez JM, et al. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J, 2004 ;5:227 - 233 被引量:1
  • 6van-de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood, 2005 ; 111 : 1067 - 1077 被引量:1
  • 7Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood, 2002 ; 100:3887 - 3896 被引量:1
  • 8Font P, Subina D, Mtnez-Chamorro C, et al. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34 + myeloblasts from patients with myelodysplastic syndrome. Leuk Res, 2006 ;30:957 - 963 被引量:1
  • 9Ogata K, Yoshida Y. Clinical implications of blast immunophenotypes in myelodysplastic syndromes. Leuk Lymphoma, 2005;46: 1269 - 1274 被引量:1
  • 10Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood, 2003 ;102:394 -403 被引量:1

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部